Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented ...
A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.
Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL. This is an ASCO Meeting ...
Since 2017, a personalized immunotherapy called Chimeric Antigen Receptor, or CAR-T cell treatment, has worked wonders to ...
From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...
Creating a functional lung using interspecies chimeric animals is an attractive albeit challenging option for lung transplantation, requiring more research on the viable conditions needed for organ ...
Chimeric Therapeutics Ltd. (AU:CHM) has released an update. Chimeric Therapeutics is strengthening its commitment to Environmental, Social, and Governance (ESG) principles by aligning with the UN’s ...
A team of researchers has reported for the first time the live birth of a monkey that contains a high proportion of cells derived from a monkey stem cell line. This 'chimeric' monkey is composed of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results